XML 86 R15.htm IDEA: XBRL DOCUMENT v3.3.0.814
Note 8 - China Operations
12 Months Ended
Aug. 31, 2015
Notes to Financial Statements  
Fair Value Disclosures [Text Block]
8. CHINA OPERATIONS
 
Effective December 31, 2014, the Company terminated its joint venture agreements with its previous joint venture in China, Tianjin Zerust, began the process of liquidating the joint venture entity, and commenced operations in China through a wholly-owned subsidiary, NTIC (Shanghai) Co. Ltd. on January 1, 2015. Effective December 31, 2014, the Company’s investment in Tianjin Zerust is reported at carrying value based on the Company’s decreased level of influence over the entity, and the Company has reclassified previously unrecognized gains on foreign currency translation from accumulated other comprehensive income. Any declines in the fair value are reflected as adjustments to the carrying value. No such adjustments were recorded during fiscal 2015.
 
The investment in Tianjin Zerust is as follows:
 
    Investment
Equity method investment – August 31, 2014   $ 2,243,524  
Equity in earnings – fiscal year 2015     132,824  
Reclassification of translation gains on foreign currency translation     (492,680 )
Investment at carrying value – August 31, 2015   $ 1,883,668  
 
The Company incurred expenses of $1,642,258 during fiscal 2015 related to the termination of the joint venture agreement with Tianjin Zerust, the initiation of the liquidation of Tianjin Zerust and the formation and initial operation of NTIC China. Such expenses consisted primarily of legal expenses and personnel expenses associated with the establishment of the subsidiary and the hiring of new personnel. These expenses are recorded as operating expenses on the consolidated statements of operations and are partially off-set by the gross margin contribution from sales of NTIC China.
 
Because of the lack of financial and other information received from Tianjin Zerust, it is possible that if and when financial and other information is received from Tianjin Zerust that the Company may need to recognize an impairment charge on its investment in Tianjin Zerust. The Company estimates that its maximum exposure in terms of an impairment charge would be approximately $1,130,200 on its investment in Tianjin Zerust, or 60% of the entire investment at carrying value, which was $1,883,668 as of August 31, 2015.